BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 26, 2004
 |  BioCentury  |  Product Development

In HBV, five is not a crowd

With two polymerase inhibitors on the market and two more in Phase III trials, the market for hepatitis B therapeutics is getting crowded. But Anadys Pharmaceuticals Inc. is betting that the shortcomings of all four leave room for it to work on a better mousetrap.

ANDS last week exercised its option to co-develop ANA380 (LB80380), a polymerase inhibitor from LG Life Sciences Ltd. that is in Phase II trials. The partners plan to develop the compound for chronic HBV infection as front-line therapy and salvage therapy for lamivudine-resistant patients.

According to Kleanthis Xanthopoulos, president and CEO of ANDS (San Diego, Calif.), shortcomings of other polymerase inhibitors include low potency, high toxicity and lack of activity against resistant strains. Although the company has not yet identified how ANA380 produces a different result, he said it...

Read the full 656 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >